HCW Biologics Inc. announced that its license agreement with WY Biotech Co., Ltd. is now fully binding, following WY Biotech's completion of due diligence. This due diligence related to HCWB’s technology transfer report, including cell line characterization, which was delivered on May 13, 2025.
WY Biotech confirmed its commitment to proceed with the development and commercialization of the licensed molecule, HCW11-006, for in vivo therapeutic applications. As a result, HCW Biologics has earned the $7.0 million upfront license fee under the amended terms of the agreement.
In addition to the upfront payment, HCWB remains eligible to receive significant development milestone payments and double-digit royalties on future product sales. Preclinical studies demonstrated HCW11-006's high effectiveness in inducing anti-tumor CD8+ T cell and NK cell responses without unwanted side effects in relevant solid tumor animal models.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.